Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

14.97
+0.38002.60%
Post-market: 14.970.00000.00%16:10 EST
Volume:598.00K
Turnover:9.01M
Market Cap:757.83M
PE:-4.32
High:15.41
Open:14.74
Low:14.61
Close:14.59
52wk High:15.41
52wk Low:5.04
Shares:50.62M
Float Shares:41.42M
Volume Ratio:0.69
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4644
EPS(LYR):-4.5871
ROE:-76.88%
ROA:-18.54%
PB:4.69
PE(LYR):-3.26

Loading ...

Regenxbio Inc - Topline Pivotal Data Expected Early Q2 2026, Bla Submission Mid-2026

THOMSON REUTERS
·
Oct 30

Regenxbio Inc. to Release Third Quarter 2025 Results

Reuters
·
Oct 29

Regenxbio CEO Curran Simpson Reports Disposal of Common Shares

Reuters
·
Oct 11

Regenxbio to Present Interim Phase II Data for Gene Therapy Sura Vec in Diabetic Retinopathy at AAO 2025

Reuters
·
Oct 09

REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%

Simply Wall St.
·
Oct 09

REGENXBIO Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 07

BRIEF-Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD

Reuters
·
Oct 06

Regenxbio Inc - Topline Pivotal Data Expected in Q4 2026

THOMSON REUTERS
·
Oct 06

Regenxbio Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet Amd

THOMSON REUTERS
·
Oct 06

Regenxbio Completes Enrollment in Pivotal Global Trials for First Gene Therapy in Wet AMD; Topline Results Expected Q4 2026

Reuters
·
Oct 06

Regenxbio Inc. CEO Curran Simpson Reports Disposal of Common Shares

Reuters
·
Oct 02

Leerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
Sep 17

CEO Curran Simpson Reports Disposal of Regenxbio Inc. Common Shares

Reuters
·
Sep 13

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Sep 08

BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii

Reuters
·
Sep 05

REGENXBIO Inc. Announces Positive 12-Month Pivotal Data for RGX-121 in Hunter Syndrome Treatment Trial

Reuters
·
Sep 05

Regenxbio Inc - Primary Endpoint of Csf Hs D2s6 Reduction Met

THOMSON REUTERS
·
Sep 05

Regenxbio Inc - Rgx-121 Improves Outcomes for Mps Ii Patients

THOMSON REUTERS
·
Sep 05

Regenxbio Inc - FDA Decision on Rgx-121 Expected by February 8, 2026

THOMSON REUTERS
·
Sep 05

REGENXBIO Inc. to Participate in Wells Fargo Healthcare Conference in Boston

Reuters
·
Aug 28